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Background: Use of depot medroxyprogesterone acetate (DMPA), often known by the brand name Depo-Provera,
has increased globally, particularly in multiple low- and middle-income countries (LMICs). As a reproductive health
technology that has scaled up in diverse contexts, DMPA is an exemplar product innovation with which to illustrate
the utility of the AIDED model for scaling up family health innovations.
Methods: We conducted a systematic review of the enabling factors and barriers to scaling up DMPA use in LMICs.
We searched 11 electronic databases for academic literature published through January 2013 (n = 284 articles), and
grey literature from major health organizations. We applied exclusion criteria to identify relevant articles from peer-
reviewed (n = 10) and grey literature (n = 9), extracting data on scale up of DMPA in 13 countries. We then mapped
the resulting factors to the five AIDED model components: ASSESS, INNOVATE, DEVELOP, ENGAGE, and DEVOLVE.
Results: The final sample of sources included studies representing variation in geographies and methodologies. We
identified 15 enabling factors and 10 barriers to dissemination, diffusion, scale up, and/or sustainability of DMPA
use. The greatest number of factors were mapped to the ASSESS, DEVELOP, and ENGAGE components.
Conclusions: Findings offer early empirical support for the AIDED model, and provide insights into scale up of
DMPA that may be relevant for other family planning product innovations.
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A puzzle in reproductive health, and public health gen-
erally, has long been why innovative products and pro-
grams spread widely and rapidly in some contexts but
fail to spread in others. Multiple models of spread focus
on active dissemination of an innovation, providing rec-
ommendations for how to facilitate or accelerate take up
[1-5], while other models have described the process of
passive diffusion of innovations [6-8]. In work described
elsewhere [9], our team identified characteristics associ-
ated with successful innovation spread – encompassing
both active dissemination and passive diffusion – and
developed a new model to capture these dynamics in the* Correspondence: leslie.curry@yale.edu
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reproduction in any medium, provided the ordomain of family health. The resulting nonlinear, com-
plex adaptive system model, called AIDED (Figure 1),
was designed for flexible application across diverse
innovation types, including products, behaviors,
organizational structures, and delivery systems. The
AIDED model thus differs from prior models of repro-
ductive health intervention scale up in that it applies to
a broader range of innovations and incorporates both ac-
tive dissemination and passive diffusion processes, fully
recognizing the complex adaptive system nature of scal-
ing up processes.
The description of the AIDED model [9] has consisted
of a synthesis of findings across a range of innovation
types and may be of use to providers and policymakers
interested in family health innovations broadly. However,
the current descriptions may be of limited use to those
interested in ‘products’ such as injectable contraceptives.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and































Figure 1 Schematic of the AIDED model for scaling up family health innovations. Legend: The figure presents the five non-linear,
interrelated actions of the AIDED model: 1) assess the landscape, 2) innovate to fit user receptivity, 3) develop support, 4) engage user groups,
and 5) devolve efforts for spreading innovation. The model suggests that successful scale up occurs within a complex adaptive system,
characterized by interdependent parts, multiple feedback loops, and several potential paths to achieve intended outcomes. Source: Bradley et al.
[9]. Copyright is held by the authors under the Creative Commons License and permission is granted for reproduction in this manuscript.
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model using results from a systematic review of the aca-
demic and grey literature about dissemination, diffusion,
scale up, and sustainability of depot medroxyprogesterone
acetate (DMPA). DMPA, often known by the brand name
Depo-Provera, is a long-acting contraceptive administered
by intramuscular injection that is an effective, convenient,
reversible, and increasingly popular family planning
method [10-14]. Recognition of these benefits, accompan-
ied by approval by the U.S. Food and Drug Administration
in 1992, catalyzed a global doubling of injectable contra-
ceptive use between 1995 and 2005, a trend that was par-
ticularly prevalent among low-income countries [15].
DMPA scale up has been described in several countries
including Bangladesh [16], Uganda [17], Ghana [15],
Vietnam [18,19], Taiwan [20], Afghanistan [21], Malawi
[22], India [23] and Zimbabwe (Rhodesia) [24]. As a well-
documented reproductive health technology that has
scaled up in diverse contexts, DMPA offers an exemplar
“product-type” innovation in the domain of family health
for illustrating the AIDED model’s usefulness. We selected
DMPA rather than other injectable contraceptives on
account of its longer duration, which is a distinguishing
feature that is advantageous in settings where access to
health care is difficult; DMPA is also the most prevalent
injectable contraceptive used globally [15,25].
Previous literature about scaling up DMPA has tended
to focus on the distribution channel, such as whether
clinic-based or community-based distribution is used. Nu-
merous findings related to the safety and efficacy of
community-based distribution (CBD) of DMPA have been
published [10-12,14,23,26-29] and recently synthesized[11] and toolkits to aid policymakers and practitioners in
scaling up community-based access to injectables have
also been produced [30-33]. By contrast, this paper seeks
to synthesize evidence about the enabling factors and bar-
riers to scale up of DMPA as a product, rather than scale
up of a particular DMPA distribution channel. Our focus
is therefore on cases in which DMPA use has spread from
a smaller number to a larger number of user groups, re-
gardless of whether that spread occurred via clinic-based
or community-based approaches. In this paper we map
the evidence about DMPA scale up to the AIDED model,
summarizing relevant peer-reviewed and grey literature to
illustrate the model with a specific product innovation,
and identify lessons for scaling up of DMPA and other
contraceptive technologies in low- and middle-income
countries.
The AIDED model
The AIDED model includes 5 non-linear, interrelated
components: 1) assess the landscape, 2) innovate to fit
user receptivity, 3) develop support, 4) engage user
groups, and 5) devolve efforts for spreading innovation
[9]. Each component captures a set of processes; this
action-based approach distinguishes the AIDED model
from other scale-up frameworks that focus on actors or
context [2-4,6,34]. The model suggests that successful
scale up occurs within a complex adaptive system, char-
acterized by interdependent parts, multiple feedback
loops, and several potential paths to achieve intended
outcomes. The AIDED model’s nonlinear nature is an-
other distinctive feature relative to existing approaches
to scale-up strategy design [1,35]. Importantly, the
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organization or community) as its unit of analysis and
mechanism of spread, in contrast to prior scale-up stud-
ies of individual behavior change [36-38].
The ASSESS component refers to assessment of the
broad landscape within a potential user group , including
the needs and wants of the user community, its absorp-
tive capacity, and the political, economic, legal/regula-
tory, technological and social conditions within its
internal and external environment. The INNOVATE
component includes designing, re-designing, and pack-
aging an innovation so that the innovation is acceptable
and perceived as advantageous by potential user groups
in their specific context or environment. These processes
of designing, re-designing, and packaging the innovation
are aimed at achieving ‘fit’ between the innovation and
the user group. In the DEVELOP component, attention
is directed to fostering enabling relationships, environ-
ments and networks among partners that can support
and facilitate spread of the innovation. Although engage-
ment occurs throughout the process of dissemination
and diffusion, the ENGAGE component involves the
specific tasks of introducing the innovation from outside
the user group to inside the user group, translating the
innovation so that user groups can assimilate the new
information, and integrating the innovation into the rou-
tine practices and social norms of the user group. Fi-
nally, the DEVOLVE component involves the initial user
groups releasing and spreading the innovation for its re-
introduction in new user groups within their peer net-
works. These user groups and their networks replicate
and release the innovation (in adapted and potentially
failed forms) in the way they see most appropriate. The
AIDED model is both descriptive of common features of
successful innovation spread, and prescriptive of pro-
cesses that should be considered by those wishing to fa-
cilitate scale up.
Methods
We conducted a systematic review of the literature on the
scale up and sustainability of DMPA in low- and middle-
income countries. We searched 11 electronic databases in-
cluding MEDLINE, CINAHL, EMBASE, Web of Science
(Science Citation Index and Social Science Citation
Index), PsycINFO, Global Health, EconLit, CSA Multi-
Search (International Bibliography of the Social Sciences,
Social Services Abstracts, and Sociological Abstracts). We
included any literature published since the earliest date
initialed in each database up to the January 2013 search
date. The keywords used to search for articles related to
DMPA were medroxyprogesterone acetate, injectable
medroxyprogesterone, injectable medroxyprogesterone
acetate, DMPA, Depo-, Depo Provera, Depo-Provera,
Depo-Provera contraceptive, and Depo-SubQ Provera104. The keywords used to search for articles related to
scaling up were replication, scale up, sustainability, diffu-
sion, dissemination, take up, innovation, diffusion of
innovation, technology transfer, information dissemin-
ation, acculturation, assimilation, fidelity, and uptake. We
used two questions to determine if an article fit our study
objective of identifying factors associated with DMPA
scale up:
(i) Does the paper specifically address factors related to
an increase in the number of individual DMPA users
within a given group or community?
(ii)Does the paper specifically address factors related to
the diffusion, dissemination, or scale up of DMPA
use from one geography to another (e.g., from village
to village, or province to province)?
If the answer to either question (i) or question (ii) was af-
firmative, the paper was included in our sample. We did
not set any minimum criteria for the scope or scale of scale
up. We included cases in which DMPA was introduced to
end user groups for whom DMPA was new, whether such
expanded delivery occurred through task shifting (e.g.,
from clinic-based providers to community-based health
workers) or a first-time introduction of DMPA into a
country or health system.
The searches yielded an initial sample of 284 unique
articles after eliminating duplicates (Figure 2). We
screened the abstracts of all articles in this initial sample
(n = 284). An article was excluded at the abstract screen-
ing stage if it did not address spread of DMPA as an in-
jectable contraceptive as its primary topic (n = 218) or if
it did not discuss the scale up or sustainability of DMPA
(n = 37). We then reviewed the full text of the articles
retained following abstract screening (n = 29). At the full
text screening stage, an article was excluded if: (1) it was
superficial in its discussion and/or did not provide em-
pirical evidence about the scale up or sustainability of
DMPA(n = 7); (2) it did not address scale up or sustain-
ability of DMPA (n = 5), did not address spread of
DMPA as an injectable contraceptive as its primary topic
(n = 3), did not address low- or middle-income countries
(n = 3); or (3) the full text of the article was not available
online (n = 1). Following the full text screening, 10 arti-
cles were retained for data extraction and analysis.
The grey literature searches targeted the publications/
resources databases and websites of the World Health
Organization (WHO), the United Nations Children’s Fund
(UNICEF), the United Nations Development Programme
(UNDP), the United Nations Population Fund (UNFPA),
the World Bank, the African Development Bank, the
Inter-American Development Bank, and the Asian Devel-
opment Bank. We also reviewed the project reports pub-









(n = 284 unique references after removing duplicates)
Number of references identified in each database
Full Text Screening  
(n = 29)
References excluded based on abstract review
(n = 255)
Reason for exclusion
Does not address DMPA spread as its primary topic (n = 218)
Does not address dissemination, diffusion, scale up, or 
sustainability of DMPA (n = 37)
References excluded based on full text review
(n = 19) 
Reason for exclusion
Does not address DMPA spread as its primary topic (n = 3)
Does not address dissemination, diffusion, scale up, or 
sustainability of DMPA (n = 5)
Only superficial description/no empirical evidence (n = 7)
Does not address low- or middle-income countries (n = 3) 
Full text is not available online (n = 1)
Language is not English, Spanish, French, or Portuguese (n = 0)
MEDLINE (n = 110)
CINAHL (n = 6)
EMBASE (n = 117)
PsycINFO (n = 5)
Global Health (n = 7)
Web of Science (n = 81)
EconLit (n = 0)
CSA Multi-Search (International Bibliography of the 
Social Sciences, Social Services Abstracts, 
Sociological Abstracts) (n = 12)
Grey literature (same screen 

















Figure 2 Peer-reviewed literature review sample selection process. Legend: The figure summarizes the results of each stage in the search
and review process for selecting the sample of peer-reviewed literature. Source: Authors.
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(USAID), the Canadian International Development
Agency (CIDA), and the Department for International De-
velopment (DFID)]. Due to the large volume of hits gener-
ated from these web site searches, the titles of all hits were
screened first. If a document appeared relevant on the
basis of its title, the full text was reviewed using the same
exclusion criteria as applied to the academic literature. Fi-
nally, we conducted purposeful searches using the same
general approach for cases widely recognized as major
DMPA implementation initiatives. This process resulted
in 9 documents that addressed the scale-up and/or sus-
tainability of DMPA in low- and middle-income countries.
Although some characteristics relevant to scale up differ
between clinic-based provision and CBD of DMPA, as our
focus was on scaling up DMPA as a product innovation
rather than scaling up a specific delivery method, we
chose to include both delivery methods in this review
in order to identify common elements and extract as
much information as possible from the limited published
literature.Data extraction from the final sample of academic arti-
cles (n = 10) and grey literature documents (n = 9) was
conducted independently by two research team mem-
bers using a pre-established data extraction form. For
each article, the data extraction process identified the
study design, geographic location, and key findings re-
lated to scale up and sustainability of DMPA use. Differ-
ences in preliminary data extraction results were
harmonized through discussion between the two team
members to arrive at a final set of factors influencing the
success of DMPA scale up and/or sustainability. Findings
were then iteratively grouped into categories of enabling
factors and barriers to scale up and/or sustainability,
with disagreements resolved through negotiated consen-
sus between the two team members.
After the final list of enabling factors and barriers was
established, two team members mapped these scale-up
determinants to the five components of the AIDED
model (ASSESS, INNOVATE, DEVELOP, ENGAGE, and
DEVOLVE). The mapping was conducted by comparing
each enabling factor or barrier against the definitions of
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more parts of the AIDED model. For example, the enab-
ling factor of “ensuring fit with cultural norms” was
mapped to both the ASSESS and INNOVATE compo-
nents because ensuring fit with cultural norms requires
identifying the extant norms (an aspect of assessment)
and then tailoring the product to be acceptable within
those norms (an aspect of innovation design and pack-
aging). This process preserved the potential for an enab-
ling factor or barrier not to match the definition of
any of the five components. Disagreements between the
two team members were resolved through negotiated
consensus.
Results
The final sample of 19 sources (10 academic articles and 9
grey literature documents) included studies representing a
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Cross-sectional interviews, questionnaires or chart review 3
Pre-post intervention without comparison group 3
Literature review or commentary 2
Simulation modeling 1
Mixed methods 3















Multiple countries (e.g., literature review) 3
Administration of DMPA
Community-based administration 13
Clinic-based administration 6These studies examined DMPA programs from 13 unique
countries; 3 studies included multiple countries. Among
the literature from which we extracted data, 5 of the stud-
ies used qualitative methods, such as in-depth interviews,
focus groups, or observations, 3 sources presented find-
ings from pre/post interventional studies, 3 used mixed
methods (in which literature reviews and quantitative ana-
lyses were supplemented by key informant interviews), 3
were cross-sectional, 2 were literature reviews or com-
mentaries, and 1 involved time-series modeling. Two of
the papers failed to report their methodologies (Table 1).
The data extraction process identified 15 enabling fac-
tors and 10 barriers to dissemination, diffusion, scale up,
and/or sustainability of DMPA, all of which were
mapped to one or more of the AIDED model compo-
nents. The ASSESS, DEVELOP, and ENGAGE compo-
nents of the AIDED model had the largest number of
factors and barriers mapped to them (Tables 2 and 3). In
the following section, we summarize the factors (or key
activities) and barriers identified in the literature as they
relate to each component of the AIDED model, and pro-
vide illustrative examples for each. We present four gen-
eral lessons characterizing the scale up of DMPA that
may also have relevance for scale up of other family
health innovations in low- and middle-income countries.
Assess
Key enabling factors
In the literature we reviewed, enabling factors that were
mapped to the ASSESS component included conducting
broad landscape and stakeholder assessments from com-
munity to international levels (n = 6), dialogue with the
community at early stages to understand cultural and re-
ligious norms relevant to contraception and family plan-
ning (n = 5), piloting to determine feasibility in the
particular context (n = 3), creating structures to ensure
use of assessment findings through implementation and
scale up (n = 1), and identifying potential sources of re-
sistance (n = 1).
Barriers
Three barriers to scale up were mapped to the ASSESS
component: misaligned government policies (e.g., favoring
provision of contraceptives by medical personnel) (n = 1),
opposition by medical professionals (n = 1) and social and
cultural norms and dynamics (n = 2). A landscape assess-
ment might have identified and addressed such barriers
early in the process, ultimately facilitating scale up.
Illustrative example
The process of conducting a comprehensive baseline as-
sessment was described as critical to the introduction of
DMPA as part of a package of family planning interven-
tions in Vietnam [18]. In 1994, guided by the Strategic
Table 2 Enabling factors for the dissemination, diffusion, scale up, or sustainability of DMPA by AIDED model
components
Enabling factor # sources
citing factor
AIDED model component(s) to
which factor was mapped
Development of delivery system supports (training of health workers/field motivators,
creation of training manuals or checklists, supply chain improvements, recruitment of
women, chart tracking)
10 Develop
Tailoring innovation to existing system capacity (community-based distribution systems
already in place, women in community health worker roles, other existing program
infrastructure (e.g., well-baby clinics, current supply chain flows))
9 Innovate, Devolve
Landscape or stakeholder assessment 6 Assess
Collaboration with stakeholders to identify or create supportive structures in the economic,
political and technological spheres
6 Assess, Develop
Use of social networks 5 Devolve
Dialogue with community at early stages 5 Assess, Engage
Effective education through social marketing regarding risks and instructions (including
community input)
4 Develop, Engage
Piloting to determine feasibility 3 Assess
Innovation design features (e.g., injectable at 3 month intervals) 3 Innovate
Ensuring ‘fit’ with cultural norms (e.g., allowing women to take injections in strict
confidence without being observed)
3 Assess, Innovate
Use of data to improve program performance 3 Engage
Nationalistic messaging (e.g., population control) 2 Develop
Adherence to religious norms (e.g., support of leaders) 1 Innovate, Develop, Engage
Identifying potential sources of resistance, such as from the professional medical
community
1 Assess
Creating structures to ensure use of assessment findings through implementation and scale
up (e.g., the same individuals that conducted the assessment remained involved
throughout the process of scaling)
1 Assess
Table 3 Barriers to the dissemination, diffusion, scale up, or sustainability of DMPA by AIDED model components
Barrier # sources
citing factor
AIDED model component(s) to
which factor was mapped
Lack of system capacity (e.g., delivery or administrative challenges, lack of equipment, supply
chain stock-outs due to mismanagement, staff burden)
5 Innovate, Develop
Rural nature of program areas (e.g., difficulties in maintaining supply chain or human
resource levels)
5 Devolve
Inadequate resources for scaled-up activities 4 Devolve
Competing alternatives (e.g., other types of family planning products such as condom,
diaphragm, or pill)
3 Develop
Misaligned government policies and priorities (e.g., preference for HIV/AIDS projects, longer
acting methods, or provision of family planning by medical personnel)
3 Assess, Develop, Devolve
Data collection challenges (e.g., insufficient contact between front line and supervisors, front
line failure to understand tools, follow-up challenges)
3 Develop
Social or cultural norms (e.g., male dominance or power, elder family member objections,
general concerns about fidelity and family size)
1 Assess, Innovate, Engage,
Lack of knowledge or awareness (e.g., inadequate counseling or patient education, lack of
patient-centered care, limited information sharing)
1 Develop, Engage
Opposition by medical professionals 1 Assess, Engage
Lack of ongoing stakeholder support (e.g., key leaders left after pilot phase) 1 Devolve
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the World Health Organization [39], the Vietnamese
government alongside several international partners
began the intervention planning process with a partici-
patory needs assessment, carried out by the Ministry of
Health, the National Committee of Population and Fam-
ily Planning, and the Vietnam Women’s Union. The pur-
pose of the assessment was to determine the suitability
and need for contraceptive introduction within a larger
initiative to strengthen quality of care in the service de-
livery system. A dissemination workshop followed in
1995, in which stakeholders reviewed and approved the
assessment findings; the pilot intervention began in
1996. Though time intensive, this process served to gen-
erate consensus on a dual goal: to improve quality while
successfully introducing DMPA to broaden the range of
contraceptive choices for women. Individuals who had
participated in the strategic assessment were subse-
quently involved in the design and management of the
pilot studies, ensuring continued responsiveness to the
issues identified through the assessment. This core team
also became the resource team to provide supervision,
guidance and mentoring in scale up efforts, as the pro-
ject grew in scale from 4 to 21 provinces (DMPA is now
available in all 64 provinces). In addition to the national
level process, tailored, focused assessments were carried
out to inform implementation at the local level. Situ-
ational analysis was conducted at each of the four pilot
sites before implementation; findings were used to im-
prove client flow, logistics and infection control prac-
tices at the sites.
Innovate
Key enabling factors
In the literature we reviewed, enabling factors mapped
to the INNOVATE component included tailoring the
innovation to the existing system capacity, such as infra-
structure for well-baby clinics and existing supply chain
flows (n = 9), creating innovative design and packaging
features (n = 3), ensuring ‘fit’ between design and socio-
cultural norms (n = 3), and tailoring innovations to suit
current system capacity (n = 9). In general, design fea-
tures for a product innovation include how the product
will be delivered to end users. In the case of DMPA, the
ability for a woman to receive DMPA injections every
three months without a daily or pericoital regimen, and
usually in a private room without others being aware of
her contraception use, were critical characteristics of the
product that enabled scale up in several low-income
contexts. These features figure prominently in the mar-
keting of DMPA and stand in contrast to other types of
contraceptive products, such as oral pills or condoms,
that are more likely to be observed by or require negoti-
ation with other household members.Barriers
Two barriers identified in the literature mapped to the
INNOVATE component: lack of system capacity for
DMPA distribution (e.g., delivery or administrative chal-
lenges, lack of equipment, supply chain stock-outs due
to mismanagement, staff burden) (n = 5) and social and
cultural norms and dynamics (n = 1).
Illustrative examples
Illustrations of the design, redesign, and packaging of
DMPA were highly diverse across the case reports. In
one case report from Rhodesia (now Zimbabwe), for in-
stance, the degree of ‘fit’ with cultural and religious
norms was defined as a key element. These norms were
manifest in a strong taboo against women controlling
fertility, with men exercising dominance over women’s
reproductive choices out of a desire to control family
size and ensure marital fidelity. DMPA’s injectable form
allowed ‘fit’ despite these norms. Administered every
3 months, DMPA enabled women to receive the injec-
tion in strict confidence, allowing women to navigate the
traditions of patriarchal authority without creating fric-
tion in their own relationships [24]. The “private accep-
tors,” as the literature refers to them, were married
women who used DMPA without consent or knowledge
of husbands. This confidential use was facilitated by mo-
bile well-baby clinics that also supplied contraceptives
and an approved system of bookkeeping that allowed
private acceptors’ records to be segregated from others
to ensure confidentiality. The scale up of DMPA in
Zimbabwe (Rhodesia) was substantial; between 1994 and
2006, the proportion of women choosing injectables for
contraception rose from 3% to 10% [15].
The importance of the messaging aspect of the innova-
tion’s design was illustrated in the experience of
Afghanistan. In addition to detailed information on ef-
fectiveness and safety, quotations from the Quran (the
holy book of Islam) on the value of birth spacing and
breastfeeding were included in the packaging of DMPA.
Each quotation was approved by religious leaders known
as mullahs to allow women to feel that their contracep-
tive choice was endorsed by the religious structures in
the community. Program staff identified the increased
social acceptability provided by this kind of packaging as
a factor in scale up of DMPA. Overall, the absolute
number of women using DMPA doubled and the pro-
portion of women in target groups using DMPA in-
creased from 14% to 40% [21].
Develop
Key enabling factors
In the literature we reviewed, enabling factors mapped to
the DEVELOP component included the development of
delivery system supports (n = 10), collaboration with
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the economic, political and technological spheres (n = 6),
effective education through social marketing (n = 4) and
nation-building messaging about DMPA’s value (n = 2).Barriers
Five barrier were related to the DEVELOP component,
suggesting the importance of directing attention during
development efforts to potential impediments. These in-
cluded lack of system capacity (n = 5), competing alter-
natives for political or consumer attention (n = 3),
misaligned government policies and priorities (n = 3),
data collection challenges (n = 3) and lack of knowledge/
awareness (n = 1).Illustrative examples
Investment in building and strengthening relationships
was common to programs that reported success in scal-
ing up. In Uganda, substantial outreach and advocacy ef-
forts included leadership from the Ministry of Health
(MOH) and its non-governmental organization (NGO)
allies; these efforts have been fully catalogued in an ad-
vocacy guide [32]. In this case, the development of co-
operative partnerships between the public and private
sector required particular attention to the political cli-
mate including key decision makers and influential
stakeholders, as well as flexibility to adapt to unforeseen
shifts in the political environment. This required MOH
and NGO partners to develop clear role definitions for
all involved; it was agreed that the public sector would
be the primary implementer, with the private sector or-
ganizations providing mainly technical assistance. This
division of labor facilitated scale up and sustainability as
the functions were largely detached from transient
funding agendas. Together, both the public and private
sectors also undertook “continuous community
sensitization” efforts, which aimed at creating awareness
and educating the community as to the availability of
DMPA [17].
In addition to developing cooperative environments
amongst stakeholders, building systems capacity that can
support the innovation’s scale up also emerged as an en-
abling factor. For instance, in Vietnam, where the intro-
duction of DMPA was framed as a quality improvement
effort, new management and supervisory practices were
introduced before the launch of the intervention, and in-
cluded management information tools such as a logbook
for clients to record side effects and other information.
This required substantial investment in training program
staff across the system, from the MOH to provinces, in-
dividual providers and field motivators. The program
adopted a philosophy and practice of supportive supervi-
sion (in contrast to inspection and attainment ofquotas), which included managers discussing service im-
plementation and problem solving with providers [18].
In India, a USAID-sponsored project introduced in
2003 aimed to scale up availability and access to DMPA
in three provinces. The project relied on a private-sector
distribution strategy using well-regarded obstetricians
and gynecologists to stress the effectiveness and safety of
DMPA; however, program managers described the lack
of public sector support as being an impediment to suc-
cess. Specifically, the absence of government endorse-
ment of DMPA in the public sector slowed the pace of
growth of the overall market. Not only did the absence
of the product from the public health system affect vol-
umes, but as a result some private providers and mar-
keters may have taken a very cautious approach to
adopting DMPA themselves [23].
In Zambia, training was essential to making providers
more confident about and comfortable with administer-
ing DMPA and managing side effects and complications.
One of the training approaches involved a popular kit
with an innovative system that categorized clients
according to lifestyle and then identified the family plan-
ning methods that would most likely meet their specific
needs. The Central Board of Health recently described
this model of profiling clients as a best practice, calling
attention to its benefit of grouping clients by needs ra-
ther than providing a generic overview of various
contraceptive methods [40]. Between 1992 and 2001–
2002, injectable use (both Noristerat and Depo-Provera)
increased from 0.1% to 4.5%; Depo-Provera was found
to be particularly popular and was finally approved for
use in the country in 2004 [40].
Engage
Key enabling factors
In the literature we reviewed, enabling factors mapped
to the ENGAGE component included: dialogue with
community at early stages and throughout implementa-
tion (n = 5), effective education through social marketing
(n = 4), use of data to improve program performance
(n = 3) and compatibility with religious norms (n = 1).
Barriers
Three barriers related to the ENGAGE component were
identified. They included social and cultural norms and
dynamics (n = 1), lack of knowledge and awareness on
the part of the community (n = 1), and opposition by
medical professionals (n = 1).
Illustrative examples
In Afghanistan, local mullahs were engaged by program
staff to carry the DMPA innovation into the community,
where the mullahs ultimately grew to play a central role
in contraceptive education [21]. Through prolonged and
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areas accepted the presence of modern birth control (of
which DMPA was one option) for the purposes of birth
spacing. While their initial role had been to approve
DMPA packaging, the mullahs soon began preaching
about the benefits of injectables at Friday morning
prayers. The involvement of these community leaders,
all of whom were men, provided additional means by
which to inform women of risks and benefits and the in-
jectables’ instructions. The close and visible participation
of mullahs in contraceptive education was reported as
one of several key factors in scale-up success.
At the time of the family planning intervention in
Vietnam [18], health care providers had historically been
paternalistic in their approach to patient care, particularly
in the realm of contraception; this orientation was
reinforced by the health care system. The family planning
initiative required a major shift in these provider norms
toward a patient-centered model of care in which a
woman’s autonomous decision regarding contraception
was supported. This shift required medical professionals
to facilitate patient choice through sharing comprehensive
information, and practicing informed consent. These
changes were encouraged by supervisors and supported
with revised patient education materials for clients
stressing voluntary choice. A related feature of the pro-
gram was aimed at increasing community involvement in
health care service planning. Pilot sites were encouraged
to seek views of clients and community and to respond to
them through action plans and follow up activities; the de-
gree of involvement was monitored and reinforced
through quality of care indicators.
Engaging community leaders proved valuable in the
introduction of injectables in Ghana and Vietnam [15].
The Navrongo Initiative in Ghana, for example, worked
with local opinion leaders and existing men’s and
women’s social networks in order to garner community
acceptance for modern family planning. Regular com-
munity gatherings were held at which influential elders
endorsed health care action committees and publicly en-
couraged open communication around reproductive
health. This form of engagement employed by the
Navrongo Initiative team was identified as central to in-
creases in women choosing injectable forms of contra-
ception offered by community providers [15]. The role
of patient counseling and one-on-one engagement with
target users has proven particularly critical in scaling up
DMPA. In part, this finding reflects the well-
documented side effects of DMPA (e.g., menstrual ir-
regularities including amenorrhea) that many women
may find worrisome and which ultimately cause some to
discontinue use. Additional benefits of counseling pa-
tients extend beyond awareness of side effects. In
Vietnam, for instance the DMPA program also resultedin greater attention to clients’ privacy and enhanced rec-
ognition of patient informed choice [18].
Devolve
Key enabling factors
In the literature we reviewed, enabling factors mapped
to the DEVOLVE component included providing ad-
equate supports such as staff training and clinic space
(n = 9) and using peer social networks (n = 5).
Barriers
Four barriers at this stage of the process included the
rural nature of target program areas (n = 5), inadequate
resources for scaled-up activities (n = 4), misaligned gov-
ernment policies and priorities (n = 3), and lack of stake-
holder support (n = 1).
Illustrative examples
Social networks were reported as a key mechanism in
the devolution of DMPA. In Rural Thailand [41], “con-
versational networks” and interpersonal influence were
central to flow of information about family planning and
contraceptive choice. Women discussed birth control
with neighbors and friends during the course of daily ac-
tivities (e.g., at the rice mill, the communal well, in the
fields). These interactions occurred across age and gen-
eration boundaries; however, class and status boundaries
were less permeable and information was less likely to
be shared across these groups. Furthermore, contracep-
tive method dominance varied widely between neighbor-
ing villages, suggesting that the interlocking networks
within a village may make villages less amenable to in-
formation from external sources.
In some circumstances, external supports facilitated
the devolution process. For instance, in Vietnam [18],
substantial attention was directed at supporting scale up
of the four pilot programs. Resources from international
donor partners and the national government were used
to develop a modular toolkit as a guide to adapting and
implementing the innovation. Developers of the guide
anticipated it would be useful for subsequent sites, yet
also expected there would need to be some adaptation
to ‘fit’ local contexts. The kit included a comprehensive
enumeration of core implementation steps from
establishing a task force and conducting situational ana-
lysis to identifying appropriate sites through to quality
improvement activities.
Discussion
This systematic review of existing empirical and grey lit-
erature identified a limited number of publications of
use in understanding the process of successful dissemin-
ation, diffusion, scale up, and sustainability of DMPA in
low- and middle- income countries. The results illustrate
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innovations. Several general lessons are suggested from
the findings and may be applicable to the scale up of
other family health innovations in low- and middle- in-
come countries.
First, the design and packaging of innovations should
be broadly conceived and iteratively refined in order to
ensure ‘fit’ with end user groups. Attributes of innovation
design and packaging are diverse in nature and form;
they may include physical properties as well as psycho-
logical or emotional aspects of messaging. Taken to-
gether, these highly diverse attributes determine the
degree to which the innovation will ‘fit’ the needs and
wants of the desired user group. Particularly in family
planning, where the role of cultural and religious context
is paramount [42] and confidentiality around product
use can be critical to innovation adoption, deep under-
standing of the potential user group is central, and is ac-
quired through an iterative process of assessment and
engagement. This understanding must be manifest in
the design and packaging of the innovation, including
the potential need for refinement as scale up unfolds. In
the case of the introduction of DMPA in Zimbabwe, un-
derstanding cultural norms such as male dominance of
sexual relationships and family planning directly in-
formed the design of features to enable women to use
DMPA without the knowledge of their husbands [43].
Importantly, design and packaging of an innovation does
not happen in isolation or at single, bounded point in
time but is rather highly iterative in nature. For instance,
as in Afghanistan, the act of engaging opinion leaders
(such as religious leaders) can include involving them in
packaging and messaging to ensure that qualities of the
innovation are compatible with norms.
Second, innovations should be embedded in existing
programs and delivery systems; this requires attention to,
and sometimes investment in, both structural and man-
agerial capacity. The embedding of the innovation
within existing systems was commonly described as a
core principle, even when investment in developing sys-
tems capacity to support the integration of the
innovation may be required [17,44,45]. Particularly in
cases of CBD of DMPA [46], the development of ad-
equate managerial capacity has proven to be essential
for quality and efficiency, for instance in order to ensure
injections are being given safely, the supply chain is
maintained, and strict confidentiality is preserved. Simi-
larly, structural features of the delivery system can
maximize ‘fit’ and therefore increase the likelihood of
scale up. In Zimbabwe (Rhodesia), having women (rather
than men) deliver injections in non-clinic settings such
as well-baby clinics and markets allowed women to use
DMPA without the knowledge of others. Systematic as-
sessment of delivery system capacity and harmonizationas feasible, particularly where financial and technical
capacity is limited, is essential [46].
Third, anticipating and managing resistance from a var-
iety of constituencies both inside and outside the target
user groups is a critical activity throughout the scale-up
process. The constituencies affected by the introduction of
the innovation may be highly diverse (e.g., medical profes-
sionals in Vietnam and husbands and mothers-in-law in
Zimbabwe (Rhodesia)). While the interests and beliefs of
some stakeholders are likely to be known in advance of
the introduction of an innovation, others may only be
identified through the assessment process. Nevertheless,
resistance must be anticipated and managed on multiple
fronts and throughout the scale-up process. Strategies for
addressing resistance may be applied in the innovation
design and packaging (e.g., the case of Afghanistan),
the development of the environment (e.g., the case of
Uganda), and in processes of engagement (e.g., the case
of Vietnam). Early and sustained engagement of health
officials from all levels can mitigate such resistance;
local core teams or ‘resource teams’ are a potentially ef-
fective mechanism for engagement [18].
Fourth, diffusive spread beyond the initial group is en-
abled by existing networks within the user groups, and
may require diverse and continuing support from exter-
nal entities. The power and potential of existing peer
networks was leveraged in several cases we reviewed
[18,41,47]. The literature we reviewed suggested spread
of family health innovations through peer networks
might not require additional external resources. In one
example from Vietnam, the external group that intro-
duced the innovation was very deliberate in investing fi-
nancial and human resources in the transfer of
knowledge activities for scale up beyond the pilot sites.
This took the form of a training kit that was intended to
provide guidance about essential programmatic elements
that could also be adapted for local context. In addition
to knowledge transfer activities, external entities may
also provide various financial and non-financial supports
to strengthen or create new user group networks to fa-
cilitate spread [18].
Limitations
This study had several limitations. First, many of the ar-
ticles in our sample did not describe all stages of the
scale-up process in equivalent levels of detail. As a re-
sult, we were unable to disaggregate our analysis in
terms of the scope, pace, or extent of scale-up in the
cases we examined. Second, the sample included few
quantitative studies; thus we were not able to evaluate
the statistical associations between each identified factor
and scale-up. Finally, as a systematic review of the aca-
demic and grey literature, this study does not include
data that is unpublished, and therefore may over-
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sured and described more easily.
Conclusion
Available empirical and grey literature about DMPA pro-
vides support, in varying degrees, for each of the 5 compo-
nents of the AIDED model. An implication of our study is
that rigorous evaluation of DMPA scale-up needs to con-
tinue and accelerate in order to support evidence-based
programming in this area. An important area for future re-
search would be to analyze the presence of the different
AIDED model components according to the scope, pace,
and extent of scale-up to determine whether more AIDED
characteristics were present in projects that were scaled-up
faster, implemented at greater scale, or sustained over a
longer period of time. Another area for future research is
the application of the AIDED model to the scale-up of dif-
ferent distribution systems for DMPA, specifically clinic-
based versus community-based, to determine if particular
AIDED model components are differentially represented
across these distribution approaches. Future research
should also specifically investigate the DEVOLVE compo-
nent of the AIDED model with respect to DMPA scale-up,
for which evidence was particularly limited in the literature
we reviewed. There is a need to better understand how so-
cial networks facilitate the spread of DMPA use within and
across end user groups and to document best practices to
facilitate such diffusion. Further research on the concrete
strategies by which front-line staff have devolved program
management and leadership to the communities for the
purposes of sustainable spread is also necessary, as this
process is the least often reported in the literature.
Understanding facilitators and barriers to the scale-up
of DMPA is useful, given the strong interest in the po-
tential of DMPA in family health and growing evidence
of the efficacy and safety of community-based distribu-
tion channels. This systematic synthesis of available lit-
erature highlights the critical importance of nuanced
aspects of ‘product-type’ innovations in family health, as
well as the importance of careful appraisal of the context
in which the innovation is being introduced. More
broadly, our investigation of the DMPA literature up-
holds the value of the AIDED model in understanding
practical scale-up challenges in reproductive health and
suggests that it may be a useful framework for public
health practitioners seeking evidence-based guidance in
scaling up an array of health interventions.
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